CDMO Platform "cdmo.jp" Launched Domestically and Internationally – Supporting Drug Discovery Ventures and Pharmaceutical Companies in CDMO Selection
The General Incorporated Association CDMO Association has officially launched "cdmo.jp," a B2B platform designed to organize and compare domestic and international CDMO information. It supports drug discovery ventures and pharmaceutical companies in selecting optimal CDMO partners. Experts from the CDMO industry provide information based on technology, development stages, manufacturing systems, and service areas. Representative Motoichi Doi stated the aim is to create an environment where drug discovery personnel can confidently choose partners.
📋 Article Processing Timeline
- 📰 Published: April 15, 2026 at 01:30
- 🔍 Collected: April 14, 2026 at 17:01
- 🤖 AI Analyzed: April 14, 2026 at 17:03 (1 min after Collected)
Japan's CDMOs possess unique technologies that are globally competitive, while some technologies are only available overseas. cdmo.jp aims to be a platform that seeks optimal solutions by considering both. The B2B platform "cdmo.jp," which organizes and compares information on domestic and international CDMOs, has officially commenced operations, targeting pharmaceutical companies and bio-ventures involved in drug discovery and CMC development. As new modalities like biopharmaceuticals and regenerative medicine evolve, the number of CDMOs worldwide has increased, leading to challenges in understanding the overall landscape and comparing potential contractors. To address these issues, CDMO industry experts will organize information and provide selection support. cdmo.jp aims to be a platform that helps companies determine "what is optimal for them" by considering technology, development stages, manufacturing systems, and service areas, rather than just a directory for finding companies. The platform prioritizes identifying possibilities with domestic CDMOs first, leveraging Japan's manufacturing, quality control, and operational strengths to support the growth of Japan-originated pharmaceuticals and technologies. However, when utilizing overseas CDMOs is rational due to technological domains, supply systems, development speed, or business strategies, cdmo.jp will leverage practical experience and networks with overseas CDMOs to find realistic optimal solutions for Japanese companies. Representative Motoichi Doi commented that CDMOs are the "unsung heroes" of the drug discovery ecosystem, and their information has not been adequately organized. He aims to create an environment where drug discovery personnel can confidently select optimal partners and advance development. Future plans for cdmo.jp include visualizing technical characteristics and service areas of CDMOs, expanding overseas CDMO coverage, preparing easily comparable information by development stage and modality, providing specific bridging and matching support, assisting overseas companies in utilizing domestic CDMOs, and expanding support for venture capital investments. cdmo.jp is operated by the General Incorporated Association CDMO Association.
FAQ
What kind of platform is cdmo.jp?
cdmo.jp is a B2B platform that helps drug discovery ventures and pharmaceutical companies select optimal CDMO (Contract Development and Manufacturing Organization) partners by organizing and comparing information on domestic and international CDMOs.
What problems does cdmo.jp solve?
It addresses challenges faced by the drug discovery field in CDMO selection, such as difficulty grasping the overall landscape of global CDMOs, understanding differences in technical capabilities and service areas, and finding overseas CDMOs when domestic options are insufficient.